Gene Variant Linked to Risk of Oral Squamous Cell Carcinoma
A study shows significant association between MTHFR C677T polymorphisms and risk of oral squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - September 7, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news
Voriconazole May Boost Risk of Squamous Cell Carcinoma in Transplant Patients Voriconazole May Boost Risk of Squamous Cell Carcinoma in Transplant Patients
Recipients of lung transplants (LT) or hematopoietic cell transplants (HCT) who are taking the antifungal voriconazole may be at increased risk of squamous cell carcinoma (SCC), researchers report.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - September 7, 2018 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news
Manual vs Automated Squamous Cell Carcinoma Antigen Assays Manual vs Automated Squamous Cell Carcinoma Antigen Assays
Does the automated Elecsys SCC assay provide comparable performance to a manual assay for determining squamous cell carcinoma antigen levels?Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 5, 2018 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Radn Tx Alone May Be Adequate for Stage I Anal Cancer in Elderly
THURSDAY, Aug. 30, 2018 -- For older patients with stage I squamous cell carcinoma of the anus, radiation alone is associated with outcomes that do not differ significantly from those of chemoradiation, according to research published in the July... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 30, 2018 Category: Pharmaceuticals Source Type: news
Alpha Tau wins approval to test cancer-targeting device in the U.S.
Image courtesy of Alpha Tau Medical.
Alpha Tau Medical can begin U.S. clinical trials of its cancer-zapping device, thanks to a new permit from the Massachusetts Radiation Control Program.
The state agency granted a Sealed Source and Device (SSD) approval to the Tel Aviv company’s Alpha DaRT (Dіffusіng Alpha-emіtters Radіatіon Therapy), which enables alpha-radiation-based cancer treatment for various types of solid tumors.
Alpha DaRT delivers high-precision alpha radiation that is released when radioactive substances decay inside the tumor, according to the company. The short-range alpha particles effectivel...
Source: Mass Device - August 21, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Gynecological Oncology Regulatory/Compliance Alpha Tau Medical Source Type: news
